Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Martina Minoli"'
Autor:
Roland Seiler, Martin Egger, Marta De Menna, Saskia Wehrli, Martina Minoli, Martina Radić, Pavel Lyatoshinsky, Raphael Hösli, Jennifer Blarer, Dominik Abt, Marianna Kruithof-de Julio
Publikováno v:
BMC Urology, Vol 23, Iss 1, Pp 1-7 (2023)
Abstract Background In intermediate-risk non-muscle invasive bladder cancer (NMIBC) clinical guidelines suggest an adjuvant instillation with a chemotherapeutic agent. However, the agent and regimen are not clearly defined. Worldwide, less than 15% o
Externí odkaz:
https://doaj.org/article/58a2d04374764b54b6fc5a2070a7d305
Autor:
Martina Minoli, Thomas Cantore, Daniel Hanhart, Mirjam Kiener, Tarcisio Fedrizzi, Federico La Manna, Sofia Karkampouna, Panagiotis Chouvardas, Vera Genitsch, Antonio Rodriguez-Calero, Eva Compérat, Irena Klima, Paola Gasperini, Bernhard Kiss, Roland Seiler, Francesca Demichelis, George N. Thalmann, Marianna Kruithof-de Julio
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
Abstract Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as
Externí odkaz:
https://doaj.org/article/506bcb5c022948ab961b87996aa3927e
Autor:
Eugenio Zoni, Martina Minoli, Cédric Bovet, Anne Wehrhan, Salvatore Piscuoglio, Charlotte K. Y. Ng, Peter C. Gray, Martin Spahn, George N. Thalmann, Marianna Kruithof-de Julio
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-18 (2019)
Abstract Background Little is known about the relationship between the metabolite profile of plasma from pre-operative prostate cancer (PCa) patients and the risk of PCa progression. In this study we investigated the association between pre-operative
Externí odkaz:
https://doaj.org/article/39c5f2b2d321454c983b249c4e06d9e6
Autor:
Roland Seiler, Martin Egger, Marta De Menna, Saskia Wehrli, Martina Minoli, Martina Radić, Pavel Lyatoshinsky, Raphael Hoesli, Jennifer Blarer, Dominik Abt, Marianna De-Kruithof Julio
Background: In intermediate risk non-muscle-invasive bladder cancer (NMIBC) clinical guidelines suggest an adjuvant instillation with a chemotherapeutic agent. However, the agent and regimen are not clearly defined. Worldwide, less than 15% of patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17d407143ab3dff65160895470f090fa
https://doi.org/10.21203/rs.3.rs-2497606/v1
https://doi.org/10.21203/rs.3.rs-2497606/v1
Autor:
Jennifer Blarer, Roland Seiler, Friedemann Krentel, Fieke Bonne, Nicola Giudici, Martina Minoli
Publikováno v:
Transl Androl Urol
Urothelial carcinomas (UC) arise from the urothelium that covers the proximal urethra, urinary bladder, and the upper urinary tract. In daily routine and clinical trials UC originating from different locations are often treated and investigated in th
Autor:
Martina Minoli, Thomas Cantore, Mirjam Kiener, Tarcisio Fedrizzi, Federico La Manna, Sofia Karkampouna, Vera Genitsch, Antonio Rodriguez, Irena Klima, Paola Gasperini, Bernhard Kiss, Roland Seiler, Francesca Demichelis, George Thalmann, Marianna Kruithof de Julio
Bladder Cancer (BLCa) inter-patient heterogeneity is considered the primary cause of tumor reoccurrence and treatment failure, suggesting that BLCa patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf86530ec02937fdad03f26c5b40fb26
https://doi.org/10.21203/rs.3.rs-1758183/v1
https://doi.org/10.21203/rs.3.rs-1758183/v1
Autor:
Martina Minoli, Thomas Cantore, Daniel Hanhart, Mirjam Kiener, Tarcisio Fedrizzi, Federico La Manna, Sofia Karkampouna, Panagiotis Chouvardas, Vera Genitsch, José Antonio Rodriguez-Calero, Eva Compérat, Irena Klima, Paola Gasperini, Bernhard Kiss, Roland Seiler-Blarer, Francesca Demichelis, George N. Thalmann, Marianna Kruithof-de Julio
Publikováno v:
Cancer Research. 83:182-182
Introduction: Interpatient heterogeneity is one of the causes of treatment failure in bladder cancer (BLCa) patients, who would therefore profit from tailor-made therapies. Toward the direction of precision medicine, patient-derived organoids (PDOs),
Autor:
Martina Minoli, Mirjam Kiener, Thomas Cantore, Tarcisio Fedrizzi, Paola Gasparini, Francesca Demichelis, George N. Thalmann, Roland Seiler-Blarer, Marianna Kruithof-de Julio
Publikováno v:
Journal of Urology. 207
Autor:
Roland Seiler, Martina Minoli, Franziaks Singer, Anne Bertolini, Ulrike Menzel, Christian Beisel, Marianna Kruithof-de Julio
Publikováno v:
Journal of Urology. 207
Autor:
Paola Gasperini, Marianna Kruithof-de Julio, Tarcisio Fedrizzi, George N. Thalmann, Roland Seiler-Blarer, Mirjam Kiener, Francesca Demichelis, Martina Minoli
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:Bladder cancer (BLCa) is the 10th most frequent cancer worldwide [1]. Non-muscle invasive (NMBC) and muscle invasive BLCa (MIBC) are the two major categories used to defi...